Leadership
Kimberly-Clark Appoints Russell Dyer Chief Corporate Affairs Officer After Kenvue Role
By News Desk ·
Key takeaways
- Russell Dyer joins Kimberly-Clark as Chief Corporate Affairs Officer after serving in the same role at Kenvue.
- Dyer spent more than eight years at Mondelēz International in senior communications and government affairs roles.
- Kimberly-Clark and Kenvue have combined into a broader consumer health and wellness platform with brands including Huggies, Kleenex and Neutrogena.
Russell Dyer has been appointed Chief Corporate Affairs Officer at Kimberly-Clark, moving from the same role at Kenvue. Hrtoday reported the appointment in November 2026.
Dyer's Corporate Affairs Mandate At Kimberly-Clark
At Kenvue, Dyer led the global corporate affairs function across external and internal communications, public and government affairs, and social impact programs. His remit at Kimberly-Clark covers corporate affairs, strategic communications, public and government affairs, reputation management, stakeholder engagement, issues management and brand communications.
Dyer spent more than eight years at Mondelēz International, where he was Senior Vice President, Chief Communications Officer and Head of Public & Government Affairs, among other roles. Before that he held corporate affairs leadership positions at Kraft Foods Group, including Vice President, Corporate Affairs, and spent nearly seven years at Weber Shandwick Worldwide.
Kimberly-Clark describes itself as a global consumer health and wellness company with brands spanning personal care, family care and everyday wellness. The company said Dyer brings experience in global communications, government affairs, corporate reputation, issues and crisis management, stakeholder engagement and brand advocacy.
Kimberly-Clark's Combined Platform With Kenvue
Kimberly-Clark and Kenvue have come together to create a broader consumer health and wellness platform, according to the company. The combined portfolio includes Huggies, Johnson's Baby, Kleenex, Scott, Kotex, Cottonelle, Depend, Listerine, Neutrogena and Tylenol.
According to akta.pro company records, Kimberly-Clark reported $16.4 billion in revenue for fiscal 2025, down from $16.8 billion the prior year, and net income of approximately $2.0 billion. The records list more than 40,000 global employees and a pending $48.7 billion acquisition of Kenvue Inc.
Board Changes And Kenvue Delisting
In November 2026, TradingView reported that Kimberly-Clark granted CEO Michael Hsu and two other executives premium-priced stock options totaling $6.6 million, with a 10-year term and vesting on December 1, 2029. The company also appointed three former Kenvue directors to its board following the acquisition.
In October 2026, Seeking Alpha reported that Kenvue was set to be delisted from the NYSE before the open as its $40 billion sale to Kimberly-Clark closes. PR Newswire reported the same month that Kimberly-Clark extended the expiration date of its exchange offer for Kenvue notes from October 27 to November 2, 2026.